Logo image of LICY

LI-CYCLE HOLDINGS CORP (LICY) Stock Fundamental Analysis

NYSE:LICY - New York Stock Exchange, Inc. - CA50202P2044 - Common Stock - Currency: USD

0.8433  -0.04 (-4.06%)

After market: 0.8433 0 (0%)

Fundamental Rating

1

LICY gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 83 industry peers in the Commercial Services & Supplies industry. LICY has a bad profitability rating. Also its financial health evaluation is rather negative. LICY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LICY had negative earnings in the past year.
In the past 5 years LICY always reported negative net income.
In the past 5 years LICY always reported negative operating cash flow.
LICY Yearly Net Income VS EBIT VS OCF VS FCFLICY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.85%, LICY is doing worse than 82.14% of the companies in the same industry.
LICY's Return On Equity of -46.73% is on the low side compared to the rest of the industry. LICY is outperformed by 78.57% of its industry peers.
Industry RankSector Rank
ROA -15.85%
ROE -46.73%
ROIC N/A
ROA(3y)-18.57%
ROA(5y)N/A
ROE(3y)-33.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LICY Yearly ROA, ROE, ROICLICY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LICY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LICY Yearly Profit, Operating, Gross MarginsLICY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

LICY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LICY has more shares outstanding
LICY has a better debt/assets ratio than last year.
LICY Yearly Shares OutstandingLICY Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M 150M
LICY Yearly Total Debt VS Total AssetsLICY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

LICY has an Altman-Z score of -1.21. This is a bad value and indicates that LICY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.21, LICY is doing worse than 84.52% of the companies in the same industry.
LICY has a Debt/Equity ratio of 1.16. This is a high value indicating a heavy dependency on external financing.
LICY has a Debt to Equity ratio of 1.16. This is in the lower half of the industry: LICY underperforms 69.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC4.9%
LICY Yearly LT Debt VS Equity VS FCFLICY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 0.60 indicates that LICY may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.60, LICY is doing worse than 90.48% of the companies in the same industry.
LICY has a Quick Ratio of 0.60. This is a bad value and indicates that LICY is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of LICY (0.54) is worse than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.6
Quick Ratio 0.54
LICY Yearly Current Assets VS Current LiabilitesLICY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.64% over the past year.
Looking at the last year, LICY shows a very strong growth in Revenue. The Revenue has grown by 36.57%.
Measured over the past years, LICY shows a very strong growth in Revenue. The Revenue has been growing by 185.06% on average per year.
EPS 1Y (TTM)25.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%241.45%
Revenue 1Y (TTM)36.57%
Revenue growth 3Y185.06%
Revenue growth 5YN/A
Sales Q2Q%78.72%

3.2 Future

The Earnings Per Share is expected to decrease by -6.84% on average over the next years.
LICY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 107.75% yearly.
EPS Next Y-75.17%
EPS Next 2Y-13.41%
EPS Next 3Y-6.84%
EPS Next 5YN/A
Revenue Next Year100.05%
Revenue Next 2Y55.81%
Revenue Next 3Y42.81%
Revenue Next 5Y107.75%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LICY Yearly Revenue VS EstimatesLICY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
LICY Yearly EPS VS EstimatesLICY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LICY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LICY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LICY Price Earnings VS Forward Price EarningsLICY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LICY Per share dataLICY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

LICY's earnings are expected to decrease with -6.84% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.41%
EPS Next 3Y-6.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LICY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LI-CYCLE HOLDINGS CORP

NYSE:LICY (2/26/2025, 8:04:00 PM)

After market: 0.8433 0 (0%)

0.8433

-0.04 (-4.06%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-14 2025-03-14/amc
Inst Owners5.99%
Inst Owner Change0%
Ins Owners5.75%
Ins Owner Change-0.22%
Market Cap29.88M
Analysts43.33
Price Target2.3 (172.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)108.56%
Min EPS beat(2)-42.75%
Max EPS beat(2)259.87%
EPS beat(4)2
Avg EPS beat(4)3.48%
Min EPS beat(4)-468.78%
Max EPS beat(4)265.58%
EPS beat(8)3
Avg EPS beat(8)-5.11%
EPS beat(12)3
Avg EPS beat(12)-35.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)55.15%
Min Revenue beat(2)17.89%
Max Revenue beat(2)92.4%
Revenue beat(4)3
Avg Revenue beat(4)53.52%
Min Revenue beat(4)-29.1%
Max Revenue beat(4)132.9%
Revenue beat(8)4
Avg Revenue beat(8)15.71%
Revenue beat(12)4
Avg Revenue beat(12)-18.83%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)51.78%
EPS NY rev (1m)0%
EPS NY rev (3m)29.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.63
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.1
EV/EBITDA N/A
EPS(TTM)-3.77
EYN/A
EPS(NY)-2.37
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.52
BVpS8.33
TBVpS8.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.85%
ROE -46.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.57%
ROA(5y)N/A
ROE(3y)-33.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.6
Quick Ratio 0.54
Altman-Z -1.21
F-ScoreN/A
WACC4.9%
ROIC/WACCN/A
Cap/Depr(3y)1835.05%
Cap/Depr(5y)1305.05%
Cap/Sales(3y)972.05%
Cap/Sales(5y)1112.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%241.45%
EPS Next Y-75.17%
EPS Next 2Y-13.41%
EPS Next 3Y-6.84%
EPS Next 5YN/A
Revenue 1Y (TTM)36.57%
Revenue growth 3Y185.06%
Revenue growth 5YN/A
Sales Q2Q%78.72%
Revenue Next Year100.05%
Revenue Next 2Y55.81%
Revenue Next 3Y42.81%
Revenue Next 5Y107.75%
EBIT growth 1Y-43.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.7%
EBIT Next 3Y22.32%
EBIT Next 5Y15.58%
FCF growth 1Y-135.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.47%
OCF growth 3YN/A
OCF growth 5YN/A